The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis

Journal of Nephrology

Volumn 26, Issue 1, 2013, Pages 48-54

  Hashemi, Pantea ^a   Sina, Bahram ^b   Rietkerk, William ^a   Safai, Bijan ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Erythropoietin; Fibrillary glomerulonephritis; Gadolinium; Nephrogenic systemic fibrosis; Renal transplant

Indexed keywords

CALCITRIOL; CITRATE CALCIUM; ERYTHROPOIETIN; FERROUS SULFATE; GADOLINIUM;

ADULT; ANEMIA; BLOOD CELL COUNT; BLOOD VESSEL INJURY; CASE REPORT; CHRONIC KIDNEY FAILURE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; ELECTRON MICROSCOPY; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; MEDICAL HISTORY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSICAL EXAMINATION; PUVA; REVIEW; RISK FACTOR; SKINFOLD THICKNESS; VITAMIN SUPPLEMENTATION;

EID: 84877087246     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000159     Document Type: Review

References (66)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001; 23(5):383-393.
2. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4): 1104-1108.
3. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(1):21-26.
4. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145(3):234-235.
5. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25(4):358.
6. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1001.
7. Cowper SE. Nephrogenic Systemic Fibrosis [ICNSFR website]. Available at http://www.icnsfr.org. Accessed March 10, 2012.
8. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114(7):563-572.
9. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48(1):55-60.
10. Deng AC, Bilu Martin D, Sina B, Gaspari A. Localized nephrogenic fibrosing dermopathy: Aberrant dermal repairing? J Am Acad Dermatol. 2008;58(2):336-339.
11. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19(2):469-473.
12. Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis. Pediatr Dev Pathol. 2007;10(5):395-402.
13. Lemy AA, Del Marmol V, Kolivras A, et al. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A singlecenter experience. J Am Acad Dermatol. 2010;63(3):389-399.
14. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-790.
15. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol. 2008;190(4):1060-1068.
16. Collidge TA, Thomson PC, Mark PB, et al. Gadoliniumenhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245(1):168-175.
17. Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial. 2008;21(2):135-139.
18. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158(2):273-280.
19. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362.
20. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56(10):3433-3441.
21. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188(2):586-592.
22. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 1999;10(3):477-484.
23. Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med. 2007;357(7):720-722.
24. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis. Mar 2003;41(3 Suppl 1):S80-83.
25. Olakanmi O, Stokes JB, Pathan S, Britigan BE. Polyvalent cationic metals induce the rate of transferrin-independent iron acquisition by HL-60 cells. J Biol Chem. 1997;272(5):2599-2606.
26. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum. 2006;35(4):208-210.
27. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214(5):584-593.
28. Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial. 2008; 21(2):150-154.
29. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007; 56(1):27-30.
30. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242(3):647-649.
31. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7(10):2425-2432.
32. Deng A, Martin DB, Spillane A, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol. 2010;37(2):204-210.
33. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W, Haroon ZA. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol. 2005; 18(3):421-430.
34. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64(2):326-333.
35. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17(1):10-16.
36. Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol. 2003;62(3):228-236.
37. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55(3):808-820.
38. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 15 1999;93(8):2627-2636.
39. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163(3):993-1000.
40. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol. 14 2007;13(22):3056-3062.
41. Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol. 2008;58(6):1025-1030.
42. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50(8): 2660-2666.
43. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25(3): 204-209.
44. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-157.
45. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004;150(5): 1050-1052.
46. Song J, Volkov S, Shea CR, et al. Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. J Cutan Pathol. 2009;36 Suppl 1:31-34.
47. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65(6):1095-1106.
48. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35(4):238-249.
49. Rosenmann E, Eliakim M. Nephrotic syndrome associated with amyloid-like glomerular deposits. Nephron. 1977;18 (5):301-308.
50. Iskandar SS, Falk RJ, Jennette JC. Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int. 1992; 42(6):1401-1407.
51. Duffy JL, Khurana E, Susin M, Gomez-Leon G, Churg J. Fibrillary renal deposits and nephritis. Am J Pathol. 1983; 113(3):279-290.
52. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003;63(4):1450-1461.
53. Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008; 19(1):34-37.
54. Fogo A, Qureshi N, Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis. 1993;22(3):367-377.
55. Samaniego M, Nadasdy GM, Laszik Z, Nadasdy T. Outcome of renal transplantation in fibrillary glomerulonephritis. Clin Nephrol. 2001;55(2):159-166.
56. Pronovost PH, Brady HR, Gunning ME, Espinoza O, Rennke HG. Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Nephrol Dial Transplant. 1996;11(5):837-842.
57. Hvala A, Ferluga D, Vizjak A, Koselj-Kajtna M. Fibrillary noncongophilic renal and extrarenal deposits: a report on 10 cases. Ultrastruct Pathol. 2003;27(5):341-347.
58. Masson RG, Rennke HG, Gottlieb MN. Pulmonary hemorrhage in a patient with fibrillary glomerulonephritis. N Engl J Med. 1992;326(1):36-39.
59. Javaid MM, Denley H, Tagboto S. Fibrillary glomerulonephritis with small fibrils in a patient with the antiphospholipid antibody syndrome successfully treated with immunosuppressive therapy. BMC Nephrol. 2007;8:7.
60. Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol. 2008;190(4):1069-1075.
61. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. Aug 2007;143(8):1025-1030.
62. Introcaso CE, Elenitsas R, Xu X, James WD. Periocular papules in nephrogenic systemic fibrosis. J Am Acad Dermatol. 2008;59(3):536-537.
63. Khurana A, Runge VM, Narayanan M, Greene JF, Jr., Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42(2):139-145.
64. Wiedemeyer K, Kutzner H, Abraham JL, et al. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. Am J Dermatopathol. 2009; 31(7):674-681.
65. Moreno-Romero JA, Segura S, Mascaro JM, Jr., et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol. 2007;157(4):783-787.
66. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2):264-267.